Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
[HTML][HTML] Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines …
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells
PHDM Prazeres, H Ferreira, PAC Costa… - International Journal …, 2023 - Taylor & Francis
Introduction Chimeric antigen receptor (CAR) cell therapy represents a hallmark in cancer
immunotherapy, with significant clinical results in the treatment of hematological tumors …
immunotherapy, with significant clinical results in the treatment of hematological tumors …
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives
BA Costa, TH Mouhieddine, RJ Ortiz… - Critical Reviews in …, 2023 - Elsevier
From the 1960s to the early 2000s, alkylating agents (eg, melphalan, cyclophosphamide,
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …
[HTML][HTML] Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell …
P Yuti, N Sawasdee, K Natungnuy… - Biomedicine & …, 2023 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA)
has been approved for treating multiple myeloma (MM). Some clinical studies reported …
has been approved for treating multiple myeloma (MM). Some clinical studies reported …
Targeting BCMA in multiple myeloma: advances in antibody-drug conjugate therapy
Simple Summary Despite the variety of drugs used to treat multiple myeloma and the ever-
lengthening survival times, a recurring problem is that many current drugs affect healthy …
lengthening survival times, a recurring problem is that many current drugs affect healthy …
Intestinal barrier functions in hematologic and oncologic diseases
The intestinal barrier is a complex structure that not only regulates the influx of luminal
contents into the systemic circulation but is also involved in immune, microbial, and …
contents into the systemic circulation but is also involved in immune, microbial, and …
Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy
Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic
hematopoietic cell transplantation recipients; however, data on CMV reactivation after …
hematopoietic cell transplantation recipients; however, data on CMV reactivation after …
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
AE Andrea, A Chiron, G Sarrabayrouse… - Frontiers in …, 2024 - frontiersin.org
In recent years, following the groundbreaking achievements of chimeric antigen receptor
(CAR) T cell therapy in hematological cancers, and advancements in cell engineering …
(CAR) T cell therapy in hematological cancers, and advancements in cell engineering …
Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide …
V Adhikarla, D Awuah, E Caserta, M Minnix… - Frontiers in …, 2024 - frontiersin.org
Introduction Cancer combination treatments involving immunotherapies with targeted
radiation therapy are at the forefront of treating cancers. However, dosing and scheduling of …
radiation therapy are at the forefront of treating cancers. However, dosing and scheduling of …